Loading...
XKRX
256840
Market cap108mUSD
Jul 09, Last price  
2,400.00KRW
1D
-1.03%
1Q
-35.74%
IPO
-5.88%
Name

BNC Korea Co Ltd

Chart & Performance

D1W1MN
XKRX:256840 chart
P/E
57.87
P/S
1.71
EPS
41.47
Div Yield, %
Shrs. gr., 5y
2.93%
Rev. gr., 5y
37.60%
Revenues
95.90b
+7.47%
0016,680,986,04617,668,446,00019,437,875,73925,248,626,00042,303,378,00080,997,490,00089,229,998,00095,899,225,000
Net income
2.84b
-78.68%
-11,879,070106,189,9722,341,922,267-5,401,184,0001,424,237,350-176,267,342,000-44,704,614,00025,686,082,00013,307,623,0002,836,572,000
CFO
7.16b
-57.12%
186,041,809-80,314,5081,928,637,3963,779,634,0003,853,347,000-11,274,273,000-5,511,677,00016,429,271,00016,696,815,0007,158,976,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in South Korea, BNC Korea Co., Ltd. focuses on the research, development, manufacturing, and distribution of various biomaterials. The company's diverse product range features hyaluronic acid (HA) and skin booster fillers, including brand names like Cutegel, Cutegel Lidocaine, FLORE Lidocaine, ChungA-an, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, all designed for the temporary reduction of facial wrinkles through physical restoration. Beyond aesthetic products, BNC Korea also manufactures Hibarry, a specialized dressing for deep-cavity wounds, which helps mitigate spinal cord adhesion during surgery. Another key medical product is GENTA Q, a white collagen sponge created to protect wounds by preventing contamination. Additionally, the company offers a line of beauty solutions, encompassing face mask gels, mild cleansing foams, and brightening peeling gels. With a significant international presence, BNC Korea exports its products to 45 countries. The firm was founded in 2007 and is headquartered in Daegu, South Korea.
IPO date
Dec 28, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT